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developing country, the human capital (employed economically active 
population) is the most important national asset. According to official 
epidemiological data from National center of Medical Statistics, prevalence of 
COPD in Ukraine is near 1%. According to opinions of Ukrainian leading 
pulmonologists, COPD in Ukraine is underdiagnosed and its prevalence rate 
could amount 6%. METHODS: Based on data from Ukrainian state statistics 
committee about number of employed economically active population in 2012 
we assessed the economic burden from COPD in two scenarios: “objective” – 
official disease prevalence rate 1%. We conducted by expert opinion of 35 leading 
pulmonologists and determined the real prevalence rate 6%. Our data about 
COPD costs per 1 employed economically active subject we received from our 
2012-2020 prospective model (Tolubaiev V., Zalis’ka O. et al. 2012).The 
calculations were discounted by social tax (18.6%) and Value Added Tax (17%). 
Exchange rate: 1USD=7.99UAH on 10.01.2013. RESULTS: According to the these 
research, number of employed economically active population in Ukraine could 
amount 20.393.267 in 2012. Number of employed economically active COPD 
patients in 2012 could be 203.933 and 1.223.596, according to “objective” and 
“real” prevalence scenarios, respectively. We estimated that in 2012 direct COPD 
costs could amount US$412.554.786 and US$2.475.328.717, indirect costs could 
amount US$244.735.489 and US$1.468.412.934, according to “objective” and “real” 
prevalence scenarios, respectively. CONCLUSIONS: Results show that value of 
COPD economic burden could enlarge with improvements in diagnostics of 
disease in Ukraine.  
 
PRS16  
UTILIZATION AND EXPENDITURE TRENDS FOR ANTI-ALLERGIC AGENTS IN THE 
MEDICAID PROGRAM  
Guo J1, Guo JJ1, Kelton CM2, Wigle PR1 
1University of Cincinnati College of Pharmacy, Cincinnati, OH, USA, 2University of Cincinnati 
College of Business, Cincinnati, OH, USA  
BACKGROUND: Allergies are among the most common chronic conditions. About 
two thirds of the population have experienced allergic symptoms in their lives. 
In the U.S., the prevalence rate is estimated to be as high as 15%, representing 40 
to 50 million individuals. Over half of the U.S. population has tested positive for 
one or more allergens. OBJECTIVES: The objective of this study was to determine 
the utilization and expenditure trends for anti-allergic agents in the U.S. 
Medicaid program. METHODS: A retrospective, descriptive analysis was 
conducted. We extracted the utilization and expenditure data from the national 
Medicaid pharmacy files, which cover 1991 first quarter to 2011 second quarter. 
The study drugs included first-generation antihistamines (e.g. 
brompheneramine, chlorpheniramine, doxylamine, and pheniramine) and 
second-generation antihistamines (e.g. azelastine, cetirizine, desloratadine, 
levocertizine, and loratadine). The quarterly prescription numbers and 
reimbursement amounts were calculated over time by summing data for 
individual drug products. The quarterly per-prescription reimbursement as a 
proxy for drug price was computed for each study drug. RESULTS: The total 
number of prescriptions for anti-allergic drugs reached a peak of 18.7 million in 
2003. The prescriptions for first-generation antihistamines dominated the 
market from 1991 to 1998, while the prescription market share for second-
generation antihistamines increased from 12.84% in 1991 first quarter to 57.17% 
in 2011 second quarter. From 1991 to 2002, the total annual Medicaid 
expenditures for antihistamines grew from $87.7 million to $757.2 million, a 
rapid increase. The average annual per-prescription price of first-generation 
antihistamines fluctuated between $8 and $17, while the per-prescription price 
of second-generation antihistamines increased from $13 to $64 from 1991 to 
2011. CONCLUSIONS: Although the U.S. Medicaid Program encourages switching 
to over-the-counter medications when available, which may be outside of the 
study’s database, utilization of and expenditures on anti-allergic medications 
have nevertheless risen substantially over the last two decades.  
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OBJECTIVES: Ventilator-associated pneumonia (VAP) is the most common 
nosocomial infection in the intensive care unit (ICU). It’s associated with 
significant morbidity, increasing the ICU and hospital length of stay (LOS), and 
raising overall costs. Literature suggests that costs could be reduced using the 
most efficient empiric therapy. The aim of this study was to assess the cost-
effectiveness (CE) of linezolid against generic vancomycin as an empiric therapy 
for VAP patients, from the health care payer’s perspective. METHODS: A 
decision-tree model was used to compare costs and effectiveness of linezolid 
(600 mg/12 hours) and vancomycin (1g/12 hours) (comparator) for a cohort of 
patients with VAP. Effectiveness measures were: microbiological success rates, 
mortality rates, ICU and ward LOS and overall costs. Effectiveness and 
epidemiologic data were collected from published literature. Local costs (2012 
US$) were obtained from Honduras´ Ministry of Health official databases (11). 
The model used a 12-week time horizon and only direct medical costs were 
considered (hospital LOS, medication costs, hematologic, gastrointestinal and 
skin adverse events and lab exams). Monte Carlo probabilistic sensitivity 
analysis (PSA) was constructed. RESULTS: Results showed linezolid as more 
effective and less expensive option for VAP. Clinical success rate was higher with 
linezolid (64.4%) against vancomicyn, (56.1%). Mortality was lower with linezolid 
(10.13% vs 15.74%). Average ICU (and ward) LOS was 18 (9) days with linezolid 
and 22 (10) days with vancomycin. Overall medical costs per patient were 
$22,825.45 with linezolid and $26,227.26 with vancomycin. CE analyses showed 
linezolid is the dominant strategy. Acceptability curves showed that linezolid 
would be cost-effective within <3 GDP per capita threshold. PSA outcomes 
support the robustness of these findings. CONCLUSIONS: This is the first CE 
study for VAP developed in Honduras. Linezolid resulted as the cost-saving 
option for treating VAP patients in the Honduran clinical environment.  
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OBJECTIVES: To determine the cost-effectiveness of adding omalizumab to 
standard therapy (ST) in patients with uncontrolled severe allergic asthma, from 
the perspective of the Brazilian private health care system. METHODS: The cost-
effectiveness analysis was based on Markov modeling, and estimated the costs 
and clinical outcomes, in a lifetime horizon, associated with ST with and without 
omalizumab add-on therapy. Clinical outcomes were expressed as clinically 
significant exacerbations (CSE) and clinically significant severe exacerbations 
(CSSE), according to the results of the phase III INNOVATE trial. Average doses, 
resource utilization per exacerbation, and omalizumab response rates were also 
obtained from the INNOVATE trial. Only direct costs were considered, including 
the acquisition costs of omalizumab and the costs of health care consumption 
related to exacerbations and routine visits. These costs were calculated from the 
perspective of the private health care payer. In the model, subjects transitioned 
between daily symptoms (optimized asthma control) and CSE or CSSE states, 
reflecting the clinical course of severe asthma. Patients could have several 
sequential CSE, or could remain exacerbation-free for prolonged periods, as 
determined by transition probabilities. Death states were separated into death 
from all causes, and death due to severe asthma exacerbation. One-way 
sensitivity-analysis (OWSA) was performed to assess model robustness. Costs 
and clinical outcomes were yearly discounted at 5%. RESULTS: The base-case 
analysis showed that in comparison with ST alone, the use of omalizumab+ST 
resulted in less exacerbations per patient (17.57 CSE and 9.27 CSSE avoided) at an 
additional cost of BRL163,190 (BRL1=USD0.492). Therefore, omalizumab ICERs 
were BRL9,289/CSE avoided and BRL17,597/CSSE avoided. OWSA confirmed the 
favorable results of the base-case for omalizumab. CONCLUSIONS: Considering 
the parameters applied, from the Brazilian private health care system 
perspective, omalizumab add-on therapy is very cost effective compared with ST 
alone in the treatment of patients with uncontrolled severe allergic asthma, 
costing less than the WHO threshold of 1GDP per capita (BRL21,252).  
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OBJECTIVES: Aclidinium bromide is a long-acting muscarinic antagonistic used 
in maintenance treatment of chronic obstructive pulmonary disease (COPD). We 
evaluated the cost-effectiveness of aclidinium 400μg twice daily as an alternative 
to tiotropium 18μg once daily for this indication in the US by conducting a 
model-based health economic study. METHODS: A cost-utility model was 
developed based on a time-in-state model structure. Patient characteristics in 
this model reflect those in aclidinium clinical studies: age >40 years; stable 
moderate-to-severe COPD; current or ex-smokers; post-salbutamol forced 
expiratory volume in 1 second (FEV1) ≥30% and <80% of predicted normal value 
and FEV1/forced vital capacity <70%. The model consists of 5 main health states 
indicating COPD severity and the level of utility, resource use, and costs. 
Treatment efficacy over 5-years time horizon was modeled using FEV1% 
predicted. Results of a network meta-analysis comparing aclidinium versus 
tiotropium were used to estimate disease progression during the first 24 weeks, 
while a common annual decline after 24 weeks was used, based on UPLIFT study 
data. Quality of life was assessed using utility scores in US patients from UPLIFT. 
Cost effectiveness was assessed as incremental cost per quality-adjusted life 
year (QALY) gained. The analysis was performed from a US third-party payer 
perspective. RESULTS: Over 5 years, 4.52 life years were accumulated for both 
aclidinium and tiotropium, with QALYs of 3.50 and 3.49, respectively, and 
marginally lower numbers of exacerbations for aclidinium. Aclidinium showed 
lower mean total health care costs vs tiotropium (US$126,274 vs US$128,591, 
respectively). In all scenario analyses performed, aclidinium was associated with 
lower costs and marginally greater QALYs vs tiotropium. Limitations include use 
of network meta-analysis to estimate treatment effect and extrapolation of trial 
results. CONCLUSIONS: These results indicate that aclidinium is potentially 
more cost-effective than tiotropium for the maintenance treatment of patients 
with moderate-to-severe COPD.  
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